ClinicalTrials.gg
CompletedNCT06041646Updated Aug 11, 2026Results posted

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

A Phase 4 interventional study of Sublingual film containing Igalmi in Bipolar Disorder, Schizophrenia and Agitation,Psychomotor, sponsored by BioXcel Therapeutics Inc. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioXcel Therapeutics Inc · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
511th of 704
29 · median 58
Started
2023
with 25 others
Phase 4
155 of 837
8 open now
Registered
758th of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 511th largest by enrollment of the 704 interventional ones that give a count, is one of 26 that started in 2023, is one of 155 in phase 4, and was the 758th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.

Read the detailed description

This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females (18 to 65 years old, inclusive) with agitation associated with schizophrenia or bipolar disorder. Subjects will be screened for eligibility within 15 days of first dose and no study procedures will occur unless subjects provide written informed consent. Subjects will receive single doses of 180 μg of Igalmi as needed for the treatment of agitation over a period of 7 days followed by a 3- day follow-up period during which time no Igalmi will be administered in an effort to characterize any potential withdrawal. Subjects will sublingually self-administer Igalmi for an agitation episode that reaches a pre-dose PEC total score of 14 or greater, as determined by a trained rater. Safety assessments will be conducted before and after each dose. If the subject's agitation is recurrent or persistent, repeat doses of 90 µg may be administered (no more than 2 repeat doses within a 24-hour period) in the absence of any safety concerns or adverse events.

03

Conditions studied

  • Bipolar Disorder
  • Schizophrenia
  • Agitation,Psychomotor
  • Schizo Affective Disorder
  • Schizophreniform Disorders

Keywords

  • Agitation
  • Schizophrenia
  • Bipolar
  • Dexmedetomidine
  • tachyphylaxis
  • tolerance
  • withdrawal
  • PRN treatment
  • Open-Label
  • PEC
  • CGI
  • ACES
  • Safety
  • Tolerability
  • Igalmi
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects between the ages of 18 to 65 years, inclusive.
  2. Subjects who have met criteria for schizophrenia, schizoaffective, or schizophreniform disorder or bipolar I or II disorder.
  3. Subjects who are currently moderate to severely agitated at least 3 days a week.
  4. Subjects who read, understand, and provide written .
  5. Subjects who are in good general health prior to study participation as determined by a detailed medical history and in the opinion of the Principal Investigator.
  6. Subjects who agree to use a medically acceptable and effective method
  7. Subjects must be willing to remain in-clinic for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with agitation caused by acute intoxication, including positive identification of alcohol by breathalyzer or drugs of abuse during screening.
  2. Use of benzodiazepines or other hypnotics or antipsychotic drugs in the 6 hours before study treatment.
  3. Subjects with congenital prolonged syndrome.
  4. Prior treatment with Igalmi
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Other
    Active Treatment - 180 mcg of Igalmi (dexmedetomidine)

    An initial dose of 180 µg of Igalmi as needed for the treatment of agitation over a period of 7 days. In the event of persistent or recurrent agitation, investigators may choose to repeat dose at 90 μg after the 2-hour time point in the absence of dose-limiting adverse events or safety concerns. A maximum of 2 repeat doses will be allowed in a 24-hour period.

    Drug: Sublingual film containing Igalmi

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

    The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

    Time frame: Baseline and 2 hours post-dose for all doses administered over 7 days.

  2. Clinical Global Impression - Improvement (CGI-I)

    The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

    Time frame: 2 hours post-dose for all doses administered over 7 days.

Secondary outcomes

  1. Number of Participants With Adverse Events During the Follow-up Period

    Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on ≥2 consecutive days of the 3-day off-treatment follow-up period.

    Time frame: Day 8 through Day 10

07

Results

Posted Jan 2, 2026

Participant flow

The study was conducted in the United States from 02Oct2023 to 29Apr2024.

Participant flow — Overall Study
MilestoneActive Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Started29
Completed28
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

The Positive and Negative Syndrome Scale-Excited Component (PEC) includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe).

Time frame:
Baseline and 2 hours post-dose for all doses administered over 7 days.
Reported as:
Mean · score on a scale
Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
score on a scaleActive Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Dose 1-10.4 ± 2.94
Dose 2-10.0 ± 3.54
Dose 3-10.1 ± 3.60
Dose 4-9.8 ± 2.55
Dose 5-11.5 ± 4.51
Dose 6-8.7 ± 3.79
Dose 7-11.0 ± NA
PrimaryClinical Global Impression - Improvement (CGI-I)

The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

Time frame:
2 hours post-dose for all doses administered over 7 days.
Reported as:
Mean · score on a scale
Clinical Global Impression - Improvement (CGI-I)
score on a scaleActive Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Dose 11.2 ± 0.50
Dose 21.2 ± 0.39
Dose 31.3 ± 0.47
Dose 41.0 ± 0.00
Dose 51.2 ± 0.41
Dose 61.3 ± 0.58
Dose 72.0 ± NA
SecondaryNumber of Participants With Adverse Events During the Follow-up Period

Evaluation of withdrawal phenomenon based on the occurrence of adverse events such as tachycardia, systolic hypertension, nausea, or vomiting and the emergence of any new adverse events on ≥2 consecutive days of the 3-day off-treatment follow-up period.

Time frame:
Day 8 through Day 10
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events During the Follow-up Period
ParticipantsActive Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Number of Participants With Adverse Events During the Follow-up Period0

Adverse events

Collected over 10 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)0/28 (0%)0/28 (0%)14/28 (50%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventActive Treatment - 180 mcg of Igalmi (Dexmedetomidine)
HeadacheNervous system disorders3/28
SomnolenceNervous system disorders3/28
Dry mouthGastrointestinal disorders3/28
HypotensionVascular disorders3/28
DizzinessNervous system disorders1/28
SyncopeNervous system disorders1/28
DyspepsiaGastrointestinal disorders1/28
Gastroesophageal reflux diseaseGastrointestinal disorders1/28
Hypoesthesia oralGastrointestinal disorders1/28
Orthostatic hypotensionVascular disorders1/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Mean45.4 ± 8.85
Sex: Female, Male
Sex: Female, Male(Participants)Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Female10
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Hispanic or Latino0
Not Hispanic or Latino28
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American13
White15
More than one race1
Unknown or Not Reported0
Diagnosis
Diagnosis(Participants)Active Treatment - 180 mcg of Igalmi (Dexmedetomidine)
Bipolar 1 or 217
Schizophrenia10
Schizoaffective disorder2
08

Study locations

2 sites
  • BioXcel Clinical Research Site
    Little Rock, Arkansas 72211, United States
  • BioXcel Clinical Research Site
    Rogers, Arkansas 72758, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2024, 6 months.

Results were first posted in Jan 2026, 1 year 8 months after primary completion.

Of 44 phase 4 interventional studies under Bipolar Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Oct 2, 2023
Primary completionActual
Apr 29, 2024
CompletionActual
Apr 29, 2024
Results first posted
Jan 2, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06041646
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Lotus Clinical Research, LLC
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Oct 2, 2023
Primary completion
Apr 29, 2024
Completion
Apr 29, 2024
Results posted
Jan 2, 2026
Last update
Aug 11, 2026

Study contacts

BioXcel MM, MD
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion